Indexed In
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- The Global Impact Factor (GIF)
- China National Knowledge Infrastructure (CNKI)
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Development of anti-HBV antivirals
4th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
March 24-26, 2014 Hilton San Antonio Airport, San Antonio, USA
Mohamad Aljofan
Accepted Abstracts: Pharmaceut Anal Acta
Abstract:
Hepatitis B virus (HBV) is the causative agent of B-type hepatitis in humans, a vaccine-preventable disease. Despite the availability of effective vaccines, globally, 2 billion people show evidence of past or current HBV infection, of which 350 million people are persistently infected, with an estimated annual increase of 1 million. There is no cure for chronic HBV infections which is associated with cirrhotic liver failure and with an increased risk of developing hepatocellular carcinoma. Hepatitis antiviral research has focused primarily on the development of inhibitors of viral polymerase through the use of nucleoside analogues. Therefore, there is an urgent need for the development of non-nucleoside compounds to be used as alternative or to complement the current therapy. To address this need, a number of the isoquinoline alkaloids were evaluated for their potential antiviral activity against HBV in vitro.